Every night, the online Belgian patent register ('eRegister') receives an update with public data that were entered or generated the preceding day on the Benelux Patent Platform, the computer application with which the Belgian Intellectual Property Office handles the registration, treatment and publication processes for patents and supplementary protection certificates.
Currently, some updates are spread over consecutive nights due to the large, weekly volume of data concerning European patents designating Belgium.
For a European patent it is possible that data about the inventor(s) are missing from the online Belgian patent register. They can be found via the link to the European patent register pending an update of the Belgian patent register.
For European patents with Unitary Effect, the authentic source of information is the European Patent Register : please refer to it.

Patent details

3969449 Title: NOUVELLES FORMES CRISTALLINES DE N-(3-(2-(2-HYDROXYÉTHOXY)-6-MORPHOLINOPYRIDIN-4-YL)-4-MÉTHYLPHÉNYL)-2(TRIFLUOROMÉTHYL)ISONICOTINAMIDE SERVANT D'INHIBITEURS DE RAF POUR LE TRAITEMENT DU CANCER

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic information

Application number:
207265612
WO application number:
IB2020054491
Type:
European patent granted for BE
Status:
Open
Publication number:
3969449
WO publication number:
WO2020230028
1rst applicant's nationality:
Translation language:
EPO publication language:
English
SPC number:

Dates

Filing date:
12/05/2020
Grant date:
12/02/2025
EP publication date:
23/03/2022
WO publication date:
19/11/2020
Claims translation received date:
Translation received date (EP publication B1):
Translation received date (EP publication B2):
Translation received date (EP publication B3):
Registration date:
12/02/2025
EP B1 publication date:
12/02/2025
EP B2 publication date:
EP B3 publication date:
Lapsed date:
Expiration date (if granted and all annual fees paid):
12/05/2040

Applicant

Name:
Novartis AG
Legal Form:
From:
12/02/2025
Address:
Lichtstrasse 35, 4056 Basel, Switzerland (CH)
To:

Inventor

1

Name:
HARLACHER, Cornelius Stephen
Legal Form:
Address:
4002 Basel, Switzerland (CH)

2

Name:
LI, Zaixing
Legal Form:
Address:
Shanghai 201203, China (CN)

3

Name:
WAYKOLE, Liladhar Murlidhar
Legal Form:
Address:
Succasunna, New Jersey 07876, United States (US)

Priority

Priority patent number:
PCT/CN2019/086595
Priority date:
13/05/2019
Priority country:
World Intellectual Property Office (WIPO) (WO)

Classification

IPC or IDT classification:
C07D 413/14; A61P 35/00; A61K 31/5375;

Publication

European Patent Bulletin

1

Issue number:
202507
Publication date:
12/02/2025
Description:
Grant (B1)

2

Issue number:
202512
Publication date:
19/03/2025
Description:
Application number/publication number of the divisional application (Art. 76) changed

Annual fee

Annual fee(s) Due Date:
02/06/2025
Annual fee number:
6
Annual fee amount:
95 Euro
Expected payer:
Last annual fee payment date:
Last annual fee paid number:
Payer:
Filing date Document type Publication Type Document Description Number of pages File Type